Sector
PharmaceuticalsOpen
₹38.41Prev. Close
₹38.17Turnover(Lac.)
₹77.74Day's High
₹41.75Day's Low
₹38.4152 Week's High
₹77.752 Week's Low
₹35.1Book Value
₹5.88Face Value
₹10Mkt Cap (₹ Cr.)
313.35P/E
22.99EPS
1.66Divi. Yield
05 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
24 May 2024
12:00 AM
BookCloser
17 Aug 2023
12:00 AM
EGM
24 May 2024
12:00 AM
AGM
Announcement Date: 24 May, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -36.34 | -38.79 | -42.93 | -45.85 |
Net Worth | 40.29 | 37.84 | 33.7 | 30.78 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0.92 | 1.51 |
yoy growth (%) | 0 | -100 | -38.83 | -78.37 |
Raw materials | 0 | 0 | -0.57 | -0.99 |
As % of sales | 0 | 0 | 62.47 | 65.65 |
Employee costs | -3.26 | -3.34 | -4.55 | -7.36 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -9.46 | 15.9 | 2.18 | -18.66 |
Depreciation | -0.37 | -0.38 | -0.41 | -2.44 |
Tax paid | 0.08 | -0.35 | -3.62 | -1.9 |
Working capital | 19.52 | 14.58 | -2.48 | -17.96 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | -100 | -38.83 | -78.37 |
Op profit growth | 385.77 | -62.33 | 1.08 | -4.7 |
EBIT growth | -154.43 | 406.44 | -120.14 | -126.88 |
Net profit growth | -160.36 | -1,181.15 | -93 | -145.01 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 173.57 | 170.28 | 196.75 | 163.64 | 133.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 173.57 | 170.28 | 196.75 | 163.64 | 133.5 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 10.37 | 12.49 | 48.44 | 39.69 | 24.39 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,614.1 | 122.93 | 3,87,276.66 | 1,181.05 | 0.84 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,567.6 | 71.3 | 1,47,802.29 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.85 | 25.37 | 1,18,061.19 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,058.65 | 56.75 | 1,03,513.97 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,138.8 | 18.33 | 95,026.5 | 849.4 | 0.7 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Kartikeya V Sarabhai
Whole-time Director
Chaula Shastri
Company Sec. & Compli. Officer
Damodar Sejpal
Independent Director
Mayur K Swedia
Independent Director
BRIJESH KHANDELWAL
Independent Director
Govindprasad Namdeo
Non Executive Director
Ajay Mayor
Non Executive Director
Bharatendu Jani
Managing Director
Mohal Kartikeya Sarabhai
Independent Director
Pushpa Robin
Independent Director
Satyen Dave
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ambalal Sarabhai Enterprises Ltd
Summary
Ambalal Sarabhai Enterprises Ltd., incorporated on June 5, 1978, houses a range of companies across multi-dimensional businesses. Each subsidiary is a distinct entity contributing its unique expertise and capabilities. It is one of the oldest pharmaceutical health care companies in India, and today through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. ASEs strength is to lead with cutting edge technology by creating strategic technology tie-ups and collaborative partnerships through our broad national and international networksThe Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. It operates in two segments, pharmaceuticals and electronics. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services. In the year 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 1998-99, the company signed agreement with B V Chiron, Netherlands for introducing their anti-cancer drugs in India.During the year 1999-2000, the company entered into
Read More
What is the Ambalal Sarabhai Enterprises Ltd share price today?
The Ambalal Sarabhai Enterprises Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹40.89 today.
What is the Market Cap of Ambalal Sarabhai Enterprises Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ambalal Sarabhai Enterprises Ltd is ₹313.35 Cr. as of 06 Mar ‘25
What is the PE and PB ratio of Ambalal Sarabhai Enterprises Ltd?
The PE and PB ratios of Ambalal Sarabhai Enterprises Ltd is 22.99 and 6.49 as of 06 Mar ‘25
What is the 52 Week High and Low of Ambalal Sarabhai Enterprises Ltd?
The 52-week high/low is the highest and lowest price at which a Ambalal Sarabhai Enterprises Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ambalal Sarabhai Enterprises Ltd is ₹35.1 and ₹77.7 as of 06 Mar ‘25
What is the CAGR of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd's CAGR for 5 Years at 19.47%, 3 Years at 9.03%, 1 Year at -18.50%, 6 Month at -36.87%, 3 Month at -29.95% and 1 Month at -20.68%.
What is the shareholding pattern of Ambalal Sarabhai Enterprises Ltd?
The shareholding pattern of Ambalal Sarabhai Enterprises Ltd is as follows:
Promoters - 31.35 %
Institutions - 0.10 %
Public - 68.55 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
